An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia - Full report

Journal of Clinical Lipidology

Volumn 8, Issue 1, 2014, Pages 29-60

  Grundy, Scott M ^a   Arai, Hidenori ^b   Barter, Philip ^c   Bersot, Thomas P ^d   Betteridge, D John ^e   Carmena, Rafael ^f   Cuevas, Ada ^g   Davidson, Michael H ^h   Genest, Jacques ⁱ   Kesäniemi, Y Antero ^j   Sadikot, Shaukat ^k   Santos, Raul D ^l   Susekov, Andrey V ^m   Sy, Rody G ⁿ   LaleTokgozoglu S ^o   Watts, Gerald F ^p   Zhao, Dong ^q  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c International Atherosclerosis Society   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^f UNIVERSITY OF VALENCIA   (Spain)

^g CLÍNICA LAS CONDES   (Chile)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ ROYAL VICTORIA HOSPITAL   (Canada)

^j UNIVERSITY OF OULU   (Finland)

^k Diabetes India ^*  (India)

^l UNIVERSITY OF SÃO PAULO   (Brazil)

^m INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

ⁿ UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^o HACETTEPE UNIVERSITY   (Turkey)

^p UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^q CAPITAL MEDICAL UNIVERSITY   (China)

more..

Author keywords

Cholesterol; Dyslipidemia; Lifestyle therapies; Lifetime risk; Metabolic syndrome; Statins

Indexed keywords

CHOLESTEROL; DYSLIPIDEMIA; LIFESTYLE THERAPIES; LIFETIME RISK; METABOLIC SYNDROME; STATINS;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; DYSLIPIDEMIAS; HEALTH PLANNING GUIDELINES; HUMANS; INTERNATIONALITY; LIFE STYLE; RISK FACTORS; SOCIETIES, MEDICAL;

EID: 84893935789     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2013.12.005     Document Type: Article

References (346)

1. Pooling Project Research Group Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project J Chronic Dis 31 1978 201 306
2. J. Stamler, D. Wentworth, and J.D. Neaton Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) JAMA 256 1986 2823 2828
3. K.M. Anderson, W.P. Castelli, and D. Levy Cholesterol and mortality: 30 years of follow-up from the Framingham Study JAMA 257 1987 2176 2180
4. M.R. Law, N.J. Wald, and S.G. Thompson By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 308 1994 367 372
5. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease JAMA 251 1984 351 364
6. J.E. Rossouw, B. Lewis, and B.M. Rifkind The value of lowering cholesterol after myocardial infarction N Engl J Med 323 1990 1112 1119
7. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
8. J. Shepherd, S.M. Cobbe, and I. Ford et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301 1307
9. S.J. Lewis, L.A. Moye, and F.M. Sacks et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial Ann Intern Med 129 1998 681 689
10. J.R. Downs, M. Clearfield, and S. Weis et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
11. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
12. G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 285 2001 1711 1718
13. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
14. P.W. Serruys, P. de Feyter, C. Macaya Lescol Intervention Prevention Study (LIPS) Investigators Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial JAMA 287 2002 3215 3222
15. J. Shepherd, G.J. Blauw, M.B. Murphy PROSPER Study Group PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
16. H. Holdaas, B. Fellström, A.G. Jardine Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo controlled trial Lancet 361 2003 2024 2031
17. P.S. Sever, B. Dahlöf, N.R. Poulter ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than-average cholesterol concentrations, in the ANGLO-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial Lancet 361 2003 1149 1158
18. H.M. Colhoun, D.J. Betteridge, P.N. Durrington CARDS Investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial Lancet 364 2004 685 696
19. J.A. de Lemos, M.A. Blazing, S.D. Wiviott Investigators Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
20. S.M. Grundy, J.I. Cleeman, C.N. Merz National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [Erratum in: Circulation. 2004;110:763] Circulation 110 2004 227 239 Review
21. T.R. Pedersen, O. Faergeman, J.J. Kastelein Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial [Erratum in: JAMA. 2005;294:3092] JAMA 294 2005 2437 2445
22. J.C. LaRosa, S.M. Grundy, D.D. Waters Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
23. K.K. Ray, C.P. Cannon, C.H. McCabe PROVE IT-TIMI 22 Investigators Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial J Am Coll Cardiol 46 2005 1405 1410
24. P. Amarenco, J. Bogousslavsky, and A. Callahan 3rd et al. High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
26. NCEP. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
27. S.C. Smith Jr., E.J. Benjamin, R.O. Bonow World Heart Federation and the Preventive Cardiovascular Nurses Association AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation Circulation 124 2011 2458 2473
28. A.L. Catapano, Z. Reiner, G. De Backer European Society of Cardiology (ESC); European Atherosclerosis Society (EAS) ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 2011 3 46
29. R.O. Bonow, L.A. Smaha, S.C. Smith Jr., G.A. Mensah, and C. Lenfant World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic Circulation 106 2002 1602 1605
30. S. Mendis, P. Puska, and B. Norrving Global Atlas on Cardiovascular Disease Prevention and Control 2011 World Health Organization Geneva
31. G. De Backer, E. Ambrosioni, and K. Borch-Johnsen et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice Eur Heart J 24 2003 1601 1610
32. J. Genest, J. Frohlich, G. Fodor, R. McPherson Working Group on Hypercholesterolemia and Other Dyslipidemias Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update Can Med Assoc J 169 2003 921 924
33. M.S. Brown, and J.L. Goldstein Familial hypercholesterolemia: A genetic defect in the low-density lipoprotein receptor N Engl J Med 294 1976 1386 1390
34. J.L. Goldstein, H.H. Hobbs, and M.S. Brown Familial hypercholesterolemia C.R. Scriver, W.S. Sly, B. Childs, The Metabolic and Molecular Bases of Inherited Disease 2001 McGraw-Hill Companies, Inc New York, NY 2863 2914
35. S.M. Grundy, L. Wilhelmsen, G. Rose, R.W. Campbell, and G. Assmann Coronary heart disease in high-risk populations: lessons from Finland Eur Heart J 11 1990 462 471
36. I. Tabas, K.J. Williams, and J. Borén Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Circulation 116 2007 1832 1844 Review
37. J. Wang, A. Razuvaev, and L. Folkersen et al. The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation Atherosclerosis 220 2012 102 109
38. E. Falk, M. Nakano, J.F. Bentzon, A.V. Finn, and R. Virmani Update on acute coronary syndromes: the pathologists' view Eur Heart J 34 2013 719 728
39. B.H. Chung, G. Tallis, V. Yalamoori, G.M. Anantharamaiah, and J.P. Segrest Liposome-like particles isolated from human atherosclerotic plaques are structurally and compositionally similar to surface remnants of triglyceride-rich lipoproteins Arterioscler Thromb 14 1994 622 635
40. J.H. Rapp, A. Lespine, and R.L. Hamilton et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunoadsorption from human atherosclerotic plaque Arterioscler Thromb 14 1994 1767 1774
41. R.J. Havel Remnant lipoproteins as therapeutic targets Curr Opin Lipidol 11 2000 615 620
42. M.M. Veniant, M.A. Sullivan, and S.K. Kim et al. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100 J Clin Invest 106 2000 1501 1510
43. T. Twickler, G.M. Dallinga-Thie, M.J. Chapman, and J.S. Cohn Remnant lipoproteins and atherosclerosis Curr Atheroscler Rep 7 2005 140 147
44. A. Varbo, M. Benn, and A. Tybjærg-Hansen et al. Remnant cholesterol as a causal risk factor for ischemic heart disease J Am Coll Cardiol 61 2013 427 436
45. J. Jeppesen, H.O. Hein, P. Suadicani, and F. Gyntelberg Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study Circulation 97 1998 1029 1036
46. D.M. Lloyd-Jones, Y. Hong, D. Labarthe on behalf of the American Heart Association Strategic Planning Task Force and Statistics Committee Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond Circulation 121 2010 586 613
47. W.T. Friedewald, R.I. Levy, and D.S. Frederickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
48. Y. Cui, R.S. Blumenthal, and J.A. Flaws et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality Arch Intern Med 161 2001 1413 1419
49. W.R. Farwell, H.D. Sesso, J.E. Buring, and J.M. Gaziano Non-high-density lipoprotein cholesterol versus low-density lipoprotein cholesterol as a risk factor for a first nonfatal myocardial infarction Am J Cardiol 96 2005 1129 1134
50. P.M. Ridker, N. Rifai, N.R. Cook, G. Bradwin, and J.E. Buring Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women JAMA 294 2005 326 333
51. J. Liu, C.T. Sempos, R.P. Donahue, J. Dorn, M. Trevisan, and S.M. Grundy Non-high density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease Am J Cardiol 98 2006 1363 1368
52. I. Holme, A.H. Aastveit, I. Jungner, and G. Walldius Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS) J Intern Med 264 2008 30 38
53. J.G. Robinson, S. Wang, B.J. Smith, and T.A. Jacobson Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk J Am Coll Cardiol 53 2009 316 322
54. D.J. Gordon, J.L. Probstfield, and R.J. Garrison et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies Circulation 79 1989 8 15
55. J.C. Fruchart, F. Sacks, and M.P. Hermans et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia Am J Cardiol 102 2008 1K 34K
56. M.J. Chapman, H.N. Ginsberg, P. Amarenco for the European Atherosclerosis Society Consensus Panel Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Eur Heart J 332 2011 1345 1361
57. T. Teramoto, J. Sasaki, and S. Ishibashi et al. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan - 2012 Version J Atheroscler Thromb 20 2013 517 523
58. P. Barter HDL-C: role as a risk modifier Atheroscler Suppl 12 2011 267 270
59. A. Keys Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease 1980 Harvard University Press Cambridge, MA
60. J. Stamler Diet and coronary heart disease Biometrics 38 Suppl 1982 95 118
61. H. Blackburn, L.O. Watkins, W.S. Agras, R.A. Carleton, and B. Falkner Primary prevention of coronary heart disease Circulation 76 1 Pt 2 1987 I164 I167
62. P. Pietinen, E. Vartiainen, R. Seppänen, A. Aro, and P. Puska Changes in diet in Finland from 1972 to 1992: impact on coronary heart disease risk Prev Med 25 1996 243 250
63. B.F. Zhou, J. Stamler, B. Dennis INTERMAP Research Group Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late 1990s: the INTERMAP study J Hum Hypertens 17 2003 623 630
64. K.T. Knoops, L.C. de Groot, and D. Kromhout et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project JAMA 22 2004 1433 1439
65. A. Menotti, M. Lanti, and D. Kromhout et al. Homogeneity in the relationship of serum cholesterol to coronary deaths across different cultures: 40-year follow-up of the Seven Countries Study Eur J Cardiovasc Prev Rehabil 15 2008 719 725
66. T.T. Fung, K.M. Rexrode, and C.S. Mantzoros et al. Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women Circulation 119 2009 1093 1100
67. D. Mozaffarian, L.J. Appel, and L. Van Horn Components of a cardioprotective diet: new insights Circulation 123 2011 2870 2891
68. S.J. Baum, P.M. Kris-Etherton, and W.C. Willett et al. Fatty acids in cardiovascular health and disease: a comprehensive update J Clin Lipidol 6 2012 216 234
69. P. Pietinen, M. Lahti-Koski, E. Vartiainen, and P. Puska Nutrition and cardiovascular disease in Finland since the early 1970s: a success story J Nutr Health Aging 5 2001 150 154 Review
70. F.J. Kok, and D. Kromhout Atherosclerosis-epidemiological studies on the health effects of a Mediterranean diet Eur J Nutr 43 Suppl 1 2004 I/2 I/5 Review
71. R.P. Mensink, P.L. Zock, A.D. Kester, and M.B. Katan Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials Am J Clin Nutr 77 2003 1146 1155
72. S.M. Grundy Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol N Engl J Med 314 1986 745 748
73. A. Keys, A. Menotti, and C. Aravanis et al. The seven countries study: 2,289 deaths in 15 years Prev Med 13 1984 141 154
74. Peoples Republic of China-United States Cardiovascular and Cardiopulmonary Epidemiology Research Group An epidemiological study of cardiovascular and cardiopulmonary disease risk factors in four populations in the Peoples Republic of China: baseline report from the P.R.C.-U.S.A. [Collaborative Study] Circulation 85 1992 1083 1096
75. D. Kromhout, B. Bloemberg, E. Feskens, A. Menotti, and A. Nissinen Saturated fat, vitamin C and smoking predict long-term population all-cause mortality rates in the Seven Countries Study Int J Epidemiol 29 2000 260 265
76. S. Dayton, M.L. Pearce, S. Hashimoto, W.J. Dixon, and U. Tomiyasu A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis Circulation 40 suppl II 1969 II1 II62
77. M. Miettinen, M.J. Karvonen, O. Turpeinen, R. Elosuo, and E. Paavilainen Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes: a twelve-year clinical trial in men and women Lancet 2 1972 835 838
78. D.J. Gordon Cholesterol lowering and total mortality B.M. Rifkind, Lowering Cholesterol in High-Risk Individuals and Populations 1995 Marcel Dekker, Inc. New York 333 348
79. D.J. Jenkins, C.W. Kendall, M. Axelsen, L.S. Augustin, and V. Vuksan Viscous and nonviscous fibres, nonabsorbable and low glycaemic index carbohydrates, blood lipids and coronary heart disease Curr Opin Lipidol 11 2000 49 56
80. P.M. Kris-Etherton, F. Hu, E. Ros, and J. Sabaté The role of tree nuts and peanuts in the prevention of coronary heart disease: multiple potential mechanisms J Nutr 138 2008 1746S 1751S
81. D.K. Banel, and F.B. Hu Effects of walnut consumption on blood lipids and other cardiovascular risk factors: a meta-analysis and systematic review Am J Clin Nutr 90 2009 56 63
82. G.E. Fraser Vegetarian diets: what do we know of their effects on common chronic diseases? Am J Clin Nutr 89 2009 1607S 1612S
83. J. Sabaté, K. Oda, and E. Ros Nut consumption and blood lipid levels: a pooled analysis of 25 intervention trials Arch Intern Med 170 2010 821 827
84. F. Sofi, R. Abbate, G.F. Gensini, and A. Casini Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and metaanalysis Am J Clin Nutr 92 2010 1189 1196
85. P.A. van den Brandt The impact of a Mediterranean diet and healthy lifestyle on premature mortality in men and women Am J Clin Nutr 94 2011 913 920
86. E. Ros, and F.B. Hu Consumption of plant seeds and cardiovascular health: epidemiologic and clinical trial evidence Circulation 128 2013 553 565
87. D.J. Jenkins, T.M. Wolever, and A.V. Rao et al. Effect on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol N Engl J Med 329 1993 21 26
88. L. Brown, B. Rosner, W.W. Willett, and F.M. Sacks Cholesterol-lowering effects of dietary fiber: a meta-analysis Am J Clin Nutr 69 1999 30 42
89. S.M. Grundy, E.H. Ahrens Jr., and J. Davignon The interaction of cholesterol absorption and cholesterol synthesis in man J Lipid Res 10 1969 304 315
90. T.A. Miettinen, P. Puska, H. Gylling, H. Vanhanen, and E. Vartiainen Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population N Engl J Med 333 1995 1308 1312
91. H. Gylling, and T.A. Miettinen Cholesterol reduction by different plant stanol mixtures and with variable fat intake Metabolism 48 1999 575 580
92. S.N. Blair, D.M. Capuzzi, S.O. Gottlieb, T. Nguyen, J.M. Morgan, and N.B. Cater Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy Am J Cardiol 86 2000 46 52
93. M.B. Katan, S.M. Grundy, P. Jones, M. Law, T. Miettinen, and R. Paoletti Stresa Workshop Participants: Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels Mayo Clin Proc 78 2003 965 978
94. M. Yokoyama, H. Origasa, M. Matsuzaki Japan EPA lipid intervention study (JELIS) Investigators Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis [Erratum in: Lancet. 2007 Jul 21;370:220] Lancet 369 2007 1090 1098
95. R. Estruch, E. Ros, J. Salas-Salvadó the PREDIMED Study Investigators Primary prevention of cardiovascular disease with a Mediterranean diet N Engl J Med 368 2013 1279 1290
96. R.N. Wolf, and S.M. Grundy Influence of weight reduction on plasma lipoproteins in obese patients Arteriosclerosis 3 1983 160 169
97. H.E. Bays, P.P. Toth, and P. Kris-Etherton et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association J Clin Lipidol 7 2013 304 383
98. H.B. Hubert, M. Feinleib, P.M. McNamara, and W.P. Castelli Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study Circulation 67 1983 968 977
99. Y.S. Park, and J.S. Kim Obesity phenotype and coronary heart disease risk as estimated by the Framingham risk score J Korean Med Sci 27 2012 243 249
100. P.D. Thompson, D. Buchner, I.L. Pina American Heart Association Council on Clinical Cardiology Subcommittee on Exercise, Rehabilitation, and Prevention; American Heart Association Council on Nutrition, Physical Activity, and Metabolism Subcommittee on Physical Activity Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity) Circulation 107 2003 3109 3116
101. L. Vanhees, N. Geladas, D. Hansen on behalf of the EACPR Writing Group Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR (Part II) Eur J Prev Cardiol 19 2012 1005 1033
102. Physical Activity Guidelines Advisory Committee report, 2008. To the Secretary of Health and Human Services. Part A. Executive summary Nutr Rev 67 2009 114 120
103. J. Li, and J. Siegrist Physical activity and risk of cardiovascular disease - a meta-analysis of prospective cohort studies Int J Environ Res Public Health 9 2012 391 407
104. S.M. Grundy Metabolic syndrome pandemic Arterioscler Thromb Vasc Biol 28 2008 629 636
105. K.G. Alberti, R.H. Eckel, S.M. Grundy International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity Circulation 120 2009 1640 1645
106. A.S. Gami, B.J. Witt, and D.E. Howard et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies J Am Coll Cardiol 49 2007 403 414
107. S. Mottillo, K.B. Filion, and J. Genest et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis J Am Coll Cardiol 56 2010 1113 1132
108. T.J. Orchard, M. Temprosa, R. Goldberg Diabetes Prevention Program Research Group The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial Ann Intern Med 142 2005 611 619
109. R.B. Goldberg, and K. Mather Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program Arterioscler Thromb Vasc Biol 32 2012 2077 2090
110. S.M. Grundy, J.I. Cleeman, S.R. Daniels American Heart Association; National Heart, Lung, and Blood Institute Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [published corrections arrear in Circulation. 2005; 112:3297 and Circulation. 2005;112:e298] Circulation 112 2005 2735 2752
111. National Institutes of Health Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report [published correction appears in Obes Res. 1998;6:464] Obes Res 6 suppl2 1998 51S 209S
112. World Health Organization Obesity: Preventing and Managing the Global Epidemic: Report on a WHO Consultation (WHO Technical Report Series 894) 2000 World Health Organization Geneva, Switzerland
113. Health Canada Canadian Guidelines for Body Weight Classification in Adults 2003 Health Canada Publications Centre Ottawa, Canada Publication ID No. 4645. ISBN 0-662-33431-0
114. N.A. Khan, F.A. McAlister, S.W. Rabkin Canadian Hypertension Education Program The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy Can J Cardiol 22 2006 583 593
115. I. Graham, D. Atar, K. Borch-Johnsen ESC Committee for Practice Guidelines European guidelines on cardiovascular disease prevention in clinical practice: executive summary Atherosclerosis 194 2007 1 45
116. K. Hara, Y. Matsushita, and M. Horikoshi et al. A proposal for the cutoff point of waist circumference for the diagnosis of metabolic syndrome in the Japanese population Diabetes Care 29 2006 1123 1124
117. R. Oka, J. Kobayashi, and K. Yagi et al. Reassessment of the cutoff values of waist circumference and visceral fat for identifying Japanese subjects at risk for the metabolic syndrome Diabetes Res Clin Pract 79 2008 474 481
118. Examination Committee of Criteria for "Obesity Disease" in Japan; Japan Society for the Study of Obesity New criteria for "obesity disease" in Japan Circ J 66 2002 987 992
119. B.F. Zhou Cooperative Meta-Analysis Group of the Working Group on Obesity in China Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults: study on optimal cut-off points of body mass index and waist circumference in Chinese adults Biomed Environ Sci 15 2002 83 96
120. K.G. Alberti, P. Zimmet, J. Shaw IDF Epidemiology Task Force Consensus Group The metabolic syndrome - a new worldwide definition Lancet 366 2005 1059 1062
121. Cholesterol Treatment Trialists' (CTT) Collaboration C. Baigent, L. Blackwell, and J. Emberson et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
122. Cholesterol Treatment Trialists' (CTT) Collaborators B. Mihaylova, J. Emberson, and L. Blackwell et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
123. M.R. Law, N.J. Wald, and A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 2003 1423
124. R.C. Pasternak, S.C. Smith Jr., C.N. Bairey-Merz American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute ACC/AHA/NHLBI clinical advisory on the use and safety of statins J Am Coll Cardiol 40 2002 567 572
125. J.M. McKenney, M.H. Davidson, T.A. Jacobson, J. Guyton National Lipid Association Statin Safety Assessment Task Force Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force Am J Cardiol 97 2006 89C 94C
126. J.C. LaRosa, T.R. Pedersen, R. Somaratne, and S.M. Wasserman Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events Am J Cardiol 111 2013 1221 1229
127. E. Bruckert, G. Hayem, S. Dejager, C. Yau, and B. Bégaud Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study Cardiovasc Drugs Ther 19 2005 403 414
128. D. Rosenbaum, J. Dallongeville, P. Sabouret, and E. Bruckert Discontinuation of statin therapy due to muscular side effects: a survey in real life Nutr Metab Cardiovasc Dis 23 2013 871 875
129. P.D. Thompson, P. Clarkson, and R.H. Karas Statin-associated myopathy JAMA 289 2003 1681 1690
130. B.A. Parker, J.A. Capizzi, and A.S. Grimaldi et al. Effect of statins on skeletal muscle function Circulation 127 2013 96 103
131. T. Bader The myth of statin-induced hepatotoxicity Am J Gastroenterol 105 2010 978 980
132. N. Sattar, D. Preiss, and H.M. Murray et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
133. D. Preiss, S.R. Seshasai, and P. Welsh et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
134. L.R. Wagstaff, M.W. Mitton, B.M. Arvik, and P.M. Doraiswamy Statin-associated memory loss: analysis of 60 case reports and review of the literature Pharmacotherapy 23 2003 871 880
135. B.A. Golomb, and M.A. Evans Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism Am J Cardiovasc Drugs 8 2008 373 418
136. C.H. Rojas-Fernandez, and J.C. Cameron Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations Ann Pharmacother 46 2012 549 557
137. H.E. Bays, P.B. Moore, M.A. Drehobl Ezetimibe Study Group Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies [Erratum in: Clin Ther. 2001;23:1601] Clin Ther 23 2001 1209 1230
138. C.P. Cannon, R.P. Giugliano, M.A. Blazing IMPROVE-IT Investigators Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes Am Heart J 156 2008 826 832
139. C. Baigent, M.J. Landray, C. Reith SHARP Investigators The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
140. M. Jun, C. Foote, and J. Lv et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
141. M. Lee, J.L. Saver, A. Towfighi, J. Chow, and B. Ovbiagele Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis Atherosclerosis 217 2011 492 498
142. M.H. Frick, O. Elo, and K. Haapa et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245
143. H.B. Rubins, S.J. Robins, and D. Collins et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 1999 410 418
144. P.L. Canner, K.G. Berge, and N.K. Wenger et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
145. P.L. Canner, C.D. Furberg, M.L. Terrin, and M.E. McGovern Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project) Am J Cardiol 95 2005 254 257
146. B.G. Brown, X.Q. Zhao, and A. Chait et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
147. A.J. Taylor, L.E. Sullenberger, H.J. Lee, J.K. Lee, and K.A. Grace Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins [Epub 2004 Nov 10. Erratum in: Circulation. 2005;111:e446. Circulation. 2004;110:3615] Circulation 110 2004 3512 3517
148. AIM-HIGH Investigators W.E. Boden, J.L. Probstfield, and T. Anderson et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
149. ClinicalTrials.gov. HPS II THRIVE. Available at: http://clinicaltrials. gov/ct2/show/NCT00461630. Accessed January 6, 2014.
150. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
151. N.E. Jelesoff, C.M. Ballantyne, A.M. Xydakis, P. Chiou, P.H. Jones, and J.R. Guyton Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia Endocr Pract 12 2006 159 164
152. P.J. Barter, C.M. Ballantyne, and R. Carmena et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel J Intern Med 259 2006 247 258
153. B. Lamarche, S. Moorjani, and P.J. Lupien et al. Apoprotein A-1 and B levels and the risk of ischemic heart disease during a 5 year follow-up of men in the Québec Cardiovascular Study Circulation 94 1996 273 278
154. A.J. Moss, R.E. Goldstein, and V.J. Marder et al. Thrombogenic factors and recurrent coronary events Circulation 99 1999 2517 2522
155. G. Walldius, I. Jungner, I. Holme, A.H. Aastveit, W. Kolar, and E. Steiner High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study Lancet 358 2001 2026 2033
156. G.J. Blake, J.D. Otvos, N. Rifai, and P.M. Ridker Low-density lipoprotein particle concentration, and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women Circulation 106 2002 1930 1939
157. R.S. Rosenson, J.D. Otvos, and D.S. Freedman Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial Am J Cardiol 90 2002 89 94
158. P.J. Talmud, E. Hawe, G.J. Miller, and S.E. Humphries Non-fasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men Arterioscler Thromb Vasc Biol 22 2002 1918 1923
159. J.P. Corsetti, W. Zareba, A.J. Moss, and C.E. Sparks Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome Atherosclerosis 177 2004 367 373
160. R. Jiang, M.B. Schulze, and T. Li et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes Diabetes Care 27 2004 1991 1997
161. I. Shai, E.B. Rimm, and S.E. Hankinson et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women. Potential implications for clinical guidelines Circulation 110 2004 2824 2830
162. A.C. St-Pierre, B. Cantin, and G.R. Dagenais et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men. 13-year follow-up data from the Quebec Cardiovascular Study Arterioscler Thromb Vasc Biol 25 2005 553 559
163. A. Sniderman, K. Williams, and J. de Graaf Non-HDL C equals apolipoprotein B: except when it does not! Curr Opin Lipidol 21 2010 518 524
164. A.D. Sniderman, K. Williams, and J.H. Contois et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circ Cardiovasc Qual Outcomes 4 2011 337 345
165. A.D. Sniderman, S. Islam, S. Yusuf, and M.J. McQueen Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study Atherosclerosis 225 2012 444 449
166. S.M. Boekholdt, B.J. Arsenault, and S. Mora et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B Levels with risk of cardiovascular events among patients treated with statins JAMA 307 2012 1302 1309
167. J.G. Robinson, S. Wang, and T.A. Jacobson Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and non high-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials Am J Cardiol 110 2012 1468 1476
168. P. Barter, A.M. Gotto, J.C. LaRosa Treating to New Targets Investigators HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310
169. V. Ramjee, L.S. Sperling, and T.A. Jacobson Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math J Am Coll Cardiol 58 2011 457 463
170. C.M. Ballantyne, J.S. Raichlen, and V.A. Cain Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial J Am Coll Cardiol 52 2008 626 632
171. S.M. Grundy, G.L. Vega, J.E. Tomassini, and A.M. Tershakovec Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial) Am J Cardiol 108 2011 40 46
172. M.A. Austin Plasma triglyceride and coronary heart disease Arterioscler Thromb 11 1991 2 14
173. G. Assmann, H. Schulte, and A. von Eckardstein Hypertriglyceridemia and elevated levels of lipoprotein(a) are risk factors for major coronary events in middle-aged men Am J Cardiol 77 1996 1179 1184
174. H. Iso, Y. Naito, and S. Sato et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women Am J Epidemiol 153 2001 490 499
175. M.A. Austin, J.L. Breslow, C.H. Hennekens, J.E. Buring, W.C. Willett, and R.M. Krauss Low-density lipoprotein subclass patterns and risk of myocardial infarction JAMA 260 1988 1917 1921
176. C.D. Gardner, S.P. Fortmann, and R.M. Krauss Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women JAMA 276 1996 875 881
177. A.C. St-Pierre, I.L. Ruel, and B. Cantin et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease Circulation 104 2001 2295 2299
178. L. Kuller, A. Arnold, and R. Tracy et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study Arterioscler Thromb Vasc Biol 22 2002 1175 1180
179. W.P. Castelli, K. Anderson, P.W. Wilson, and D. Levy Lipids and risk of coronary heart disease. The Framingham Study Ann Epidemiol 2 1992 23 28
180. S. Yusuf, S. Hawken, S. Ounpuu INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 2004 937 952
181. M.J. O'Donnell, D. Xavier, L. Liu INTERSTROKE investigators Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study Lancet 376 2010 112 123
182. T. McLaughlin, F. Abbasi, K. Cheal, J. Chu, C. Lamendola, and G. Reaven Use of metabolic markers to identify overweight individuals who are insulin resistant Ann Intern Med 139 2003 802 809
183. N.C. Bhalodkar, S. Blum, and E.A. Enas Accuracy of the ratio of triglycerides to high-density lipoprotein cholesterol for predicting low-density lipoprotein cholesterol particle sizes, phenotype B, and particle concentrations among Asian Indians Am J Cardiol 97 2006 1007 1009
184. V. Bittner, B.D. Johnson, and I. Zineh et al. The triglyceride/high- density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE) Am Heart J 157 2009 548 555
185. F. Hadaegh, D. Khalili, A. Ghasemi, M. Tohidi, F. Sheikholeslami, and F. Azizi Triglyceride/HDL-cholesterol ratio is an independent predictor for coronary heart disease in a population of Iranian men Nutr Metab Cardiovasc Dis 19 2009 401 408
186. D. Gasevic, J. Frohlich, G.B. Mancini, and S.A. Lear The association between triglyceride to high-density-lipoprotein cholesterol ratio and insulin resistance in a multiethnic primary prevention cohort Metabolism 61 2012 583 589
187. H.T. Kang, J.H. Yoon, and J.Y. Kim et al. The association between the ratio of triglyceride to HDL-C and insulin resistance according to waist circumference in a rural Korean population Nutr Metab Cardiovasc Dis 22 2012 1054 1060
188. B.G. Nordestgaard, M.J. Chapman, and K. Ray et al. European Atherosclerosis Society Consensus Panel: Lipoprotein(a) as a cardiovascular risk factor: current status Eur Heart J 31 2010 2844 2853
189. Lp-PLA(2) Studies Collaboration A. Thompson, P. Gao, and L. Orfei et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies Lancet 375 2010 1536 1544
190. P.M. Ridker C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus J Am Coll Cardiol 49 2007 2129 2138
191. J.P. Casas, T. Shah, A.D. Hingorani, J. Danesh, and M.B. Pepys C-reactive protein and coronary heart disease: a critical review J Intern Med 264 2008 295 314
192. M.H. Davidson, C.M. Ballantyne, and T.A. Jacobson et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists J Clin Lipidol 5 2011 338 367
193. P.W. Wilson, M. Pencina, P. Jacques, J. Selhub, R Sr D'Agostino, and C.J. O'Donnell C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study Circ Cardiovasc Qual Outcomes 1 2008 92 97
194. N.R. Cook, N.P. Paynter, and C.B. Eaton et al. Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative Circulation 125 2012 1748 1756
195. Emerging Risk Factors Collaboration C-reactive protein, fibrinogen, and cardiovascular disease prediction N Engl J Med 367 2012 1310 1320
196. J. Perk, G. De Backer, and H. Gohlke et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012) Eur Heart J 33 2012 1635 1701
197. G. Assmann, H. Schulte, P. Cullen, and U. Seedorf Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study Eur J Clin Invest 37 2007 925 932
198. S.E. Ramsay, R.W. Morris, P.H. Whincup, A.O. Papacosta, M.C. Thomas, and S.G. Wannamethee Prediction of coronary heart disease risk by Framingham and SCORE risk assessments varies by socioeconomic position: results from a study in British men Eur J Cardiovasc Prev Rehabil 18 2011 186 193
199. C. Lorenzo, K. Williams, K.J. Hunt, and S.M. Haffner The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes Diabetes Care 30 2007 8 13
200. P. Pelletier, A. Lapointe, and N. Laflamme et al. Discordances among different tools used to estimate cardiovascular risk in postmenopausal women Can J Cardiol 25 2009 e413 e416
201. M.R. Patt, L.R. Yanek, T.F. Moy, and D.M. Becker Assessment of global coronary heart disease risk in overweight and obese African-American women Obes Res 11 2003 660 667
202. C.U. Correll, A.M. Frederickson, J.M. Kane, and P. Manu Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs J Clin Psychiatry 67 2006 575 583
203. J.R. Jaumdally, G.Y. Lip, and C. Varma Traditional risk factors for coronary atherosclerosis in Indo Asians: the need for a reappraisal Curr Pharm Des 12 2006 1611 1621
204. B.J. Arsenault, J.S. Rana, and E.S. Stroes et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women J Am Coll Cardiol 55 2009 35 41
205. O.H. Franco, J.M. Massaro, J. Civil, M.R. Cobain, B. O'Malley, and R.B. D'Agostino Sr. Trajectories of entering the metabolic syndrome: the Framingham Heart Study Circulation 120 2009 1943 1950
206. S.G. Wannamethee The metabolic syndrome and cardiovascular risk in the British Regional Heart Study Int J Obes (Lond) 32 Suppl 2 2008 S25 S29
207. S.G. Wannamethee, A.G. Shaper, L. Lennon, and R.W. Morris Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus Arch Intern Med 165 2005 2644 2650
208. G. Assmann, P. Cullen, and H. Schulte Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study Circulation 105 2002 310 315
209. H.W. Hense, H. Schulte, H. Lowel, G. Assmann, and U. Keil Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts Eur Heart J 24 2003 937 945
210. H. Arai, Y. Kokubo, and M. Watanabe et al. Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study J Atheroscler Thromb 20 2013 195 203
211. S. Kathiresan, J.D. Otvos, and L.M. Sullivan et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study Circulation 113 2006 20 29
212. P. Greenland, R.O. Bonow, B.H. Brundage American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computer Tomography); Society of Atherosclerosis Imaging and Prevention; Society of Cardiovascular Computer Tomography ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) Circulation 115 2007 402 426
213. J.A. Rumberger, R.S. Schwartz, D.B. Simons, P.F. Sheedy III, W.D. Edwards, and L.A. Fitzpatrick Relation of coronary calcium determined by electron beam computed tomography and lumen narrowing determined by autopsy Am J Cardiol 73 1994 1169 1173
214. J.A. Rumberger, D.B. Simons, L.A. Fitzpatrick, P.F. Sheedy, and R.S. Schwartz Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study Circulation 92 1995 2157 2162
215. M.J. Budoff, D. Georgiou, and A. Brody et al. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: a multicenter study Circulation 93 1996 898 904
216. A.D. Guerci, L.A. Spadaro, and J.J. Popma et al. Relation of coronary calcium score by electron beam computed tomography to arteriographic findings in asymptomatic and symptomatic adults Am J Cardiol 79 1997 128 133
217. A. Schmermund, D. Baumgart, and G. Gorge et al. Measuring the effect of risk factors on coronary atherosclerosis: coronary calcium score versus angiographic disease severity J Am Coll Cardiol 31 1998 1267 1273
218. D.H. O'Leary, J.F. Polak, R.A. Kronmal, T.A. Manolio, G.L. Burke, and S.K. Wolfson Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group N Engl J Med 340 1999 14 22
219. A.R. Folsom, R.A. Kronmal, and R.C. Detrano et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA) Arch Intern Med 168 2008 1333 1339
220. V. Nambi, L. Chambless, and A.R. Folsom et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study J Am Coll Cardiol 55 2010 1600 1607
221. J.M. Wardlaw, M.D. Stevenson, and F. Chappell et al. Carotid artery imaging for secondary stroke prevention: both imaging modality and rapid access to imaging are important Stroke 40 2009 3511 3517
222. J.M. U-King-Im, V. Young, and J.H. Gillard Carotid-artery imaging in the diagnosis and management of patients at risk of stroke Lancet Neurol 8 2009 569 580
223. S.M. Grundy Age as a risk factor: you are as old as your arteries Am J Cardiol 83 1999 1455 1457
224. P. Greenland, L. LaBree, S.P. Azen, T.M. Doherty, and R.C. Detrano Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals JAMA 291 2004 210 215
225. J. Sung, S.J. Lim, and Y. Choe et al. Comparison of the coronary calcium score with the estimated coronary risk Coron Artery Dis 19 2008 475 479
226. S.E. Elias-Smale, R.V. Proença, and M.T. Koller et al. Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study J Am Coll Cardiol 56 2010 1407 1414
227. T.M. Okwuosa, P. Greenland, and H. Ning et al. Distribution of coronary artery calcium scores by Framingham 10-year risk strata in the MESA (Multi-Ethnic Study of Atherosclerosis) potential implications for coronary risk assessment J Am Coll Cardiol 57 2011 1838 1845
228. R. Tota-Maharaj, M.J. Blaha, and J.W. McEvoy et al. Coronary artery calcium for the prediction of mortality in young adults < 45 years old and elderly adults > 75 years old Eur Heart J 33 2012 2955 2962
229. J. Yeboah, J.J. Carr, and J.G. Terry et al. Computed tomography-derived cardiovascular risk markers, incident cardiovascular events, and all-cause mortality in nondiabetics: the Multi-Ethnic Study of Atherosclerosis Eur J Prev Cardiol 2013 [E-pub ahead of print]
230. G. Youssef, N. Kalia, S. Darabian, and M.J. Budoff Coronary calcium: new insights, recent data, and clinical role Curr Cardiol Rep 15 2013 325
231. D.M. Lloyd-Jones, P.W. Wilson, and M.G. Larson et al. Framingham risk score and prediction of lifetime risk for coronary heart disease Am J Cardiol 94 2004 20 24
232. M.J. Pencina, R.B. D'Agostino, A.S. Beiser, M.R. Cobain, and R.S. Vasan Estimating lifetime risk of developing high serum total cholesterol: adjustment for baseline prevalence and single-occasion measurements Am J Epidemiol 165 2007 464 472
233. M.J. Pencina, RB Sr D'Agostino, M.G. Larson, J.M. Massaro, and R.S. Vasan Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study Circulation 119 2009 3078 3084
234. J. Hippisley-Cox, C. Coupland, J. Robson, and P. Brindle Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using Q Research database BMJ 341 2010 c6624
235. J.D. Berry, A. Dyer, and X. Cai et al. Lifetime risks of cardiovascular disease N Engl J Med 366 2012 321 329
236. D.M. Lloyd-Jones, M.G. Larson, A. Beiser, and D. Levy Lifetime risk of developing coronary heart disease Lancet 353 1999 89 92
237. D.M. Lloyd-Jones, P.W. Wilson, and M.G. Larson et al. Lifetime risk of coronary heart disease by cholesterol levels at selected ages Arch Intern Med 163 2003 1966 1972
238. D.M. Lloyd-Jones, E.P. Leip, and M.G. Larson et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age Circulation 113 2006 791 798
239. D.M. Lloyd-Jones, A.R. Dyer, R. Wang, M.L. Daviglus, and P. Greenland Risk factor burden in middle age and lifetime risks for cardiovascular and non-cardiovascular death (Chicago Heart Association Detection Project in Industry) Am J Cardiol 99 2007 535 540
240. A.K. Marma, J.D. Berry, H. Ning, S.D. Persell, and D.M. Lloyd-Jones Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006 Circ Cardiovasc Qual Outcomes 3 2010 8 14
241. N. Allen, J.D. Berry, H. Ning, L. Van Horn, A. Dyer, and D.M. Lloyd-Jones Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the Cardiovascular Lifetime Risk Pooling Project Circulation 125 2012 37 44
242. J.T. Wilkins, H. Ning, J. Berry, L. Zhao, A.R. Dyer, and D.M. Lloyd-Jones Lifetime risk and years lived free of total cardiovascular disease JAMA 308 2012 1795 1801
243. K.N. Karmali, and D.M. Lloyd-Jones Adding a life-course perspective to cardiovascular-risk communication Nat Rev Cardiol 10 2013 111 115
244. J. Hippisley-Cox, C. Coupland, and Y. Vinogradova et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2 BMJ 336 2008 1475 1482
245. G.S. Collins, and D.G. Altman Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2 BMJ 344 2012 e4181
246. D. Laurier, P.C. Nguyen, B. Cazelles, and P. Segond Estimation of CHD risk in a French working population using a modified Framingham model. The PCV-METRA Group J Clin Epidemiol 471 1994 1353 1364
247. Y. Liao, D.L. McGee, R.S. Cooper, and M.B. Sutkowski How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts Am Heart J 137 1999 837 845
248. A. Menotti, P.E. Puddu, and M. Lanti Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study Eur Heart J 21 2000 365 370
249. RB Sr D'Agostino, S. Grundy, L.M. Sullivan, P. Wilson CHD Risk Prediction Group Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation JAMA 286 2001 180 187
250. T.F. Thomsen, M. Davidsen, H. Ibsen, T. Jørgensen, G. Jensen, and K. Borch-Johnsen A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD and the Copenhagen Risk Score [Erratum in: J Cardiovasc Risk. 2001;8:391] J Cardiovasc Risk 8 2001 291 297 Review
251. Diverse Population Collaborative Group Prediction of mortality from coronary heart disease among diverse populations: is there a common predictive function? Heart 88 2002 222 228
252. P. Brindle, J. Emberson, and F. Lampe et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study BMJ 327 2003 1267
253. J.P. Empana, P. Ducimetière, D. Arveiler PRIME Study Group Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study Eur Heart J 24 2003 1903 1911
254. J. Marrugat, R. D'Agostino, and L. Sullivan et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas J Epidemiol Community Health 57 2003 634 863
255. J. Liu, Y. Hong, and RB Sr D'Agostino et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study JAMA 291 2004 2591 2599
256. Asia Pacific Cohort Studies Collaboration F. Barzi, A. Patel, and D. Gu et al. Cardiovascular risk prediction tools for populations in Asia J Epidemiol Community Health 61 2007 115 121
257. K. Eichler, M.A. Puhan, J. Steurer, and L.M. Bachmann Prediction of first coronary events with the Framingham score: a systematic review Am Heart J 153 2007 722 731
258. C.K. Chow, R. Joshi, D.S. Celermajer, A. Patel, and B.C. Neal Recalibration of a Framingham risk equation for a rural population in India J Epidemiol Community Health 63 2009 379 385
259. P. Marques-Vidal, N. Rodondi, and M. Bochud et al. Predictive accuracy of original and recalibrated Framingham risk score in the Swiss population Int J Cardiol 133 2009 346 353
260. N. Rodondi, I. Locatelli, and D. Aujesky et al. Health ABC Study. Framingham risk score and alternatives for prediction of coronary heart disease in older adults PLoS One 7 2012 e34287
261. A. Menotti, A. Keys, and D. Kromhout et al. Inter-cohort differences in coronary heart disease mortality in the 25-year follow-up of the Seven Countries Study Eur J Epidemiol 9 1993 527 536
262. T.C. Campbell, B. Parpia, and J. Chen Diet, lifestyle, and the etiology of coronary artery disease: the Cornell China study Am J Cardiol 82 1998 18T 21T
263. H. Yokokawa, S. Yasumura, and K. Tanno et al. Serum low-density lipoprotein to high-density lipoprotein ratio as a predictor of future acute myocardial infarction among men in a 2.7-year cohort study of a Japanese northern rural population J Atheroscler Thromb 18 2011 89 98
264. R.B. Singh, I.L. Suh, and V.P. Singh et al. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention J Hum Hypertens 14 2000 749 763
265. R.A. Hayward, H.M. Krumholz, D.M. Zulman, J.W. Timbie, and S. Vijan Optimizing statin treatment for primary prevention of coronary artery disease Ann Intern Med 152 2010 69 77
266. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
267. S. Kathiresan A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction N Engl J Med 358 2008 2299 2300
268. B.A. Ference, W. Yoo, and I. Alesh et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis J Am Coll Cardiol 60 2012 2631 2639
269. T.J. Anderson, J. Grégoire, and R.A. Hegele et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 29 2013 151 167
270. R.A. Hayward, and H.M. Krumholz Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health Circ Cardiovasc Qual Outcomes 5 2012 2 5
271. H. Ledford Cholesterol limits lose their luster. Revised guidelines for heart health are set to remove from target-based approach Nature 494 2013 410 411
272. N.J. Wald, and M.R. Law A strategy to reduce cardiovascular disease by more than 80% [Erratum in: BMJ. 2003;327:586. BMJ. 2006;60:823] BMJ 326 2003 1419
273. E. Lonn, J. Bosch, K.K. Teo, P. Pais, D. Xavier, and S. Yusuf The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions Circulation 122 2010 2078 2088
274. C.R. Elley, A.K. Gupta, and R. Webster et al. The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials PLoS One 7 2012 e52145
275. D.S. Wald, J.K. Morris, and N.J. Wald Randomized polypill crossover trial in people aged 50 and over PLoS One 7 2012 e41297
276. Indian Polycap Study (TIPS) S. Yusuf, P. Pais, and R. Afzal et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial Lancet 373 2009 1341 1351
277. PILL Collaborative Group A. Rodgers, A. Patel, and O. Berwanger et al. An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk PLoS One 6 2011 e19857
278. C.G. Milhos, M.J. Salas, and O. Santana The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review Cardiol Rev 18 2010 298 304
279. S. Ma, and C.C. Ma Recent development in pleiotropic effects of statins on cardiovascular disease through regulation of transforming growth factor-beta superfamily Cytokine Growth Factor Rev 22 2011 167 175
280. K.E. Porter, and N.A. Turner Statins and myocardial remodelling: cell and molecular pathways Expert Rev Mol Med 13 2011 e22
281. J. Davignon Pleiotropic effects of pitavastatin Br J Clin Pharmacol 73 2012 518 535
282. C. Baigent, A. Keech, P.M. Kearney Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [Erratum in: Lancet. 2008;371:2084. Lancet. 2005;366:1358] Lancet 366 2005 1267 1278
283. A. Misra, P. Chowbey, B.M. Makkar Consensus Group Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management J Assoc Physicians India 57 2009 163 170
284. K.F. Eriksson, and F. Lindgarde Prevention of type 2 (non-insulin- dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study Diabetologia 34 1997 891 898
285. X.R. Pan, G.W. Li, and Y.H. Hu et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study Diabetes Care 20 1997 537 544
286. J. Tuomilehto, J. Lindström, J.G. Eriksson Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 2001 1343 1350
287. W.C. Knowler, E. Barrett-Connor, S.E. Fowler Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
288. American College of Sports Medicine ACSM's Guidelines for Exercise Testing and Prescription 9th Ed. 2013 Lippincott Williams and Wilkins Philadelphia
289. S.M. Grundy Metabolic syndrome: a multiplex cardiovascular risk factor J Clin Endocrinol Metab 92 2007 399 404
290. American Heart Association Nutrition Committee A.H. Lichtenstein, L.J. Appel, and M. Brands et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee Circulation 114 2006 82 96
291. National Institute for Health and Clinical Excellence The National Collaborating Centre for Primary Care NICE Clinical Guideline 71: Identification and management of familial hypercholesterolaemia 2008 Royal College of General Practitioners London
292. S.R. Daniels, S.S. Gidding, S.D. de Ferranti National Lipid Association Expert Panel on Familial Hypercholesterolemia Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia J Clin Lipidol 5 2011 S30 S37
293. A.C. Goldberg, P.N. Hopkins, and P.P. Toth et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia J Clin Lipidol 5 2011 133 140
294. G.F. Watts, D.R. Sullivan, N. Poplawski Familial Hypercholesterolaemia Australasia Network Consensus Group (Australian Atherosclerosis Society) Familial hypercholesterolaemia: a model of care for Australasia Atheroscler Suppl 12 2011 221 263
295. G.R. Thompson Lipoprotein apheresis Curr Opin Lipidol 21 2010 487 491
296. C. Stefanutti, and U. Julius Lipoprotein apheresis: state of the art and novelties Atheroscler Suppl 14 2013 19 27
297. F. Wiesbauer, H. Blessberger, and D. Azar et al. Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or = 40 years of age) Eur Heart J 30 2009 1073 1079
298. M.J. Murphy, X. Sheng, T.M. MacDonald, and L. Wei Hypertriglyceridemia and acute pancreatitis JAMA Intern Med 173 2013 162 164
299. R.A. Hayward, T.P. Hofer, and S. Vijan Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem Ann Intern Med 145 2006 520 530
300. H.M. Krumholz, and R.A. Hayward Shifting views on lipid lowering therapy BMJ 341 2010 c3531
301. N.J. Stone, J. Robinson, and A.H. Lichtenstein et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2013 [Epub ahead of print]
302. M.P. Solano, and R.B. Goldberg Lipid management in type 2 diabetes Clin Diabetes 24 2006 27 32
303. F. Civeira International Panel on Management of Familial Hypercholesterolemia Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia Atherosclerosis 173 2004 55 68
304. T.S. Polonsky, and G.L. Bakris Chronic kidney disease: a coronary heart disease equivalent? Lancet 380 2012 783 785
305. A.I. Adler UKPDS-modelling of cardiovascular risk assessment and lifetime simulation of outcomes Diabetes Med 25 Suppl 2 2008 41 46
306. S.G. Wannamethee, A.G. Shaper, P.H. Whincup, L. Lennon, and N. Sattar Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors Arch Intern Med 171 2011 404 410
307. M. Tonelli, P. Muntner, A. Lloyd Alberta Kidney Disease Network Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study Lancet 380 2012 807 814
308. K.C. Hoang, H. Ghandehari, V.A. Lopez, M.G. Barboza, and N.D. Wong Global coronary heart disease risk assessment of individuals with the metabolic syndrome in the U.S Diabetes Care 31 2008 1405 1409
309. T. Teramoto, J. Sasaki, and H. Ueshima et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese J Atheroscler Thromb 14 2007 45 50
310. L. Mascitelli, and M.R. Goldstein Statins for people at low risk of cardiovascular disease Lancet 380 2012 1816
311. D.H. Newman, V. Saini, and H. Brody et al. Statins for people at low risk of cardiovascular disease Lancet 380 2012 1814
312. M.S. Brown, and J.L. Goldstein Biomedicine. Lowering LDL-not only how low, but how long? Science 311 2006 1721 1723
313. D. Steinberg, and S.M. Grundy The case for treating hypercholesterolemia at an earlier age: moving toward consensus J Am Coll Cardiol 60 2012 2640 2642
314. M. Domanski, D. Lloyd-Jones, V. Fuster, and S. Grundy Can we dramatically reduce the incidence of coronary heart disease? Nat Rev Cardiol 8 2011 721 725
315. J.M. Walsh, and M. Pignone Drug treatment of hyperlipidemia in women JAMA 291 2004 2243 2252
316. M. Kendrick Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? BMJ 334 2007 983
317. R.N. Bukkapatnam, N.B. Gabler, and W.R. Lewis Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis Prev Cardiol 13 2010 84 90
318. P.M. Ridker, E. Danielson, F.A. Fonseca Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
319. S. Mora, R.J. Glynn, J. Hsia, J.G. MacFadyen, J. Genest, and P.M. Ridker Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials Circulation 121 2010 1069 1077
320. S.M. Grundy Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy Nat Rev Drug Discov 5 2006 295 309
321. World Health Organization. Tobacco. Available at: http://www.who.int/ mediacentre/factsheets/fs339/en/index.html. Accessed January 6, 2014.
322. M. Ezzati, A.D. Lopez, A. Rodgers, S. Vander Hoorn, C.J. Murray Comparative Risk Assessment Collaborating Group Selected major risk factors and global and regional burden of disease Lancet 360 2002 1347 1360
323. Action to Control Cardiovascular Risk in Diabetes Study Group H.C. Gerstein, M.E. Miller, and R.P. Byington et al. Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
324. J.S. Skyler, R. Bergenstal, R.O. Bonow American Diabetes Association; American College of Cardiology Foundation; American Heart Association Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Diabetes Care 32 2009 187 192
325. P.S. Jellinger, D.A. Smith, and A.E. Mehta et al. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis Endocr Pract 18 Suppl 1 2012 1 78
326. T.J. Orchard, T. Costacou, A. Kretowski, and R.W. Nesto Type 1 diabetes and coronary artery disease Diabetes Care 29 2006 2528 2538
327. American Diabetes Association Standards of medical care in diabetes-2012 Diabetes Care 35 Suppl 1 2012 S11 S63
328. M. Barylski, S. Nikfar, D.P. Mikhailidis Lipid and Blood Pressure Meta-Analysis Collaboration Group Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy-A meta-analysis of 11 randomized controlled trials involving 21,295 participants Pharmacol Res 72 2013 35 44
329. W. Hou, J. Lv, and V. Perkovic et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis Eur Heart J 34 2013 1807 1817
330. C. Wanner, V. Krane, W. März German Diabetes and Dialysis Study Investigators Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248
331. F.M. Sacks, A.M. Tonkin, and J. Shepherd et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project Circulation 102 2000 1893 1900
332. J.C. LaRosa, S.M. Grundy, J.J. Kastelein, J.B. Kostis, and H. Greten Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study) Am J Cardiol 100 2007 747 752
333. C.P. Cannon, E. Braunwald, C.H. McCabe Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
334. C.P. Cannon The IDEAL cholesterol: lower is better JAMA 294 2005 2492 2494
335. C.P. Cannon, B.A. Steinberg, S.A. Murphy, J.L. Mega, and E. Braunwald Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 48 2006 438 445
336. A. Sachdeva, C.P. Cannon, and P.C. Deedwania et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines Am Heart J 157 2009 111 117.e2
337. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
338. J.J. Kastelein, W.A. van der Steeg, I. Holme TNT Study Group; IDEAL Study Group Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment Circulation 117 2008 3002 3009
339. C.M. Ballantyne, B. Pitt, J. Loscalzo, V.A. Cain, and J.S. Raichlen Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial) Am J Cardiol 111 2013 506 509
340. ACCORD Study Group H.N. Ginsberg, M.B. Elam, and L.C. Lovato et al. Effects of combination lipid therapy in type 2 diabetes mellitus [Erratum in N Engl J Med. 2010;6;362:1748] N Engl J Med 362 2010 1563 1574
341. M. Elam, L.C. Lovato, and H. Ginsberg Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective Curr Opin Lipidol 22 2011 55 61
342. D. Kromhout, E.J. Giltay, J.M. Geleijnse Alpha Omega Trial Group Collaborators (73) n-3 fatty acids and cardiovascular events after myocardial infarction N Engl J Med 363 2010 2015 2026
343. ORIGIN Trial Investigators J. Bosch, H.C. Gerstein, and G.R. Dagenais et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia N Engl J Med 367 2012 309 318
344. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
345. S.E. Inzucchi, R.M. Bergenstal, and J.B. Buse et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 55 2012 1577 1596
346. E.S. Ford, W.H. Giles, and A.H. Mokdad The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III J Am Coll Cardiol 43 2004 1791 1796